Efficacy and safety of first-line avelumab treatment in patients with stage IV metastatic merkel cell carcinoma a preplanned interim analysis of a clinical trial Academic Article uri icon

Overview

MeSH Major

  • Adenocarcinoma
  • Lung Neoplasms
  • Mucins
  • Mutation
  • Receptor, Epidermal Growth Factor
  • ras Proteins

abstract

  • clinicaltrials.gov Identifier: NCT02155647.

publication date

  • September 2018

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5885245

Digital Object Identifier (DOI)

  • 10.1001/jamaoncol.2018.0077

PubMed ID

  • 29566106

Additional Document Info

start page

  • e180077

volume

  • 4

number

  • 9